OLD Mission Capital LLC Buys Shares of 14,977 argenex SE $ARGX

Key Points

• OLD Mission Capital LLC has invested approximately $8.86 million in argenex SE, acquiring 14,977 shares during the first quarter.
• Analysts have a consensus rating of "Buy" for argenex, with a projected average target price of $766.50, indicating positive investor sentiment.
• argenex reported quarterly earnings of $3.74 per share, beating expectations and showcasing significant revenue growth of $866.79 million during the same period.

OLD Mission Capital LLC purchased a new position in shares of argenex SE (NASDAQ:ARGX - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 14,977 shares of the company's stock, valued at approximately $8,864,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Rakuten Securities Inc. increased its stake in shares of argenex by 56.4% in the 1st quarter. Rakuten Securities Inc. now owns 61 shares of the company's stock valued at $36,000 after acquiring an additional 22 shares in the last quarter. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of argenex in the 4th quarter valued at $38,000. WPG Advisers LLC bought a new stake in shares of argenex in the 1st quarter valued at $37,000. Golden State Wealth Management LLC bought a new stake in shares of argenex in the 1st quarter valued at $44,000. Finally, Brooklyn Investment Group increased its stake in shares of argenex by 102.7% in the 1st quarter. Brooklyn Investment Group now owns 75 shares of the company's stock valued at $44,000 after acquiring an additional 38 shares in the last quarter. Institutional investors own 60.32% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on ARGX shares. Piper Sandler lifted their price target on shares of argenex from $750.00 to $820.00 and gave the company an "overweight" rating in a research report on Tuesday, August 26th. Guggenheim lifted their price target on shares of argenex from $1,060.00 to $1,070.00 and gave the company a "buy" rating in a research report on Friday, August 1st. Royal Bank Of Canada assumed coverage on shares of argenex in a report on Monday, August 25th. They set an "outperform" rating and a $850.00 price objective on the stock. Baird R W raised shares of argenex from a "hold" rating to a "strong-buy" rating in a report on Tuesday, May 13th. Finally, Deutsche Bank Aktiengesellschaft raised shares of argenex from a "hold" rating to a "buy" rating in a report on Tuesday, July 8th. Two equities research analysts have rated the stock with a Strong Buy rating and twenty-one have given a Buy rating to the company. According to MarketBeat, the company currently has an average rating of "Buy" and an average price target of $772.84.

argenex Stock Down 0.8%

argenex stock traded down $5.79 during midday trading on Tuesday, reaching $706.41. The stock had a trading volume of 348,854 shares, compared to its average volume of 375,052. argenex SE has a 12 month low of $510.05 and a 12 month high of $716.62. The firm's 50-day moving average price is $614.60 and its 200 day moving average price is $599.63. The firm has a market capitalization of $43.23 billion, a PE ratio of 36.23, a P/E/G ratio of 0.81 and a beta of 0.41.

argenex (NASDAQ:ARGX - Get Free Report) last announced its quarterly earnings results on Thursday, July 31st. The company reported $3.74 earnings per share for the quarter, beating the consensus estimate of $2.84 by $0.90. argenex had a return on equity of 21.06% and a net margin of 40.98%.The firm had revenue of $866.79 million for the quarter, compared to analysts' expectations of $776.82 million. Equities research analysts expect that argenex SE will post 3.13 EPS for the current year.

argenex Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.